Standout Papers

Relation of Left Ventricular Mass and Geometry to Morbidity and Mortality in Uncomplicated Es... 1991 2026 2002 2014 1.9k
  1. Relation of Left Ventricular Mass and Geometry to Morbidity and Mortality in Uncomplicated Essential Hypertension (1991)
    Michael J. Koren, Richard B. Devereux et al. Annals of Internal Medicine
  2. Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events (2015)
    Jennifer G. Robinson, Michel Farnier et al. New England Journal of Medicine
  3. Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events (2015)
    Marc S. Sabatine, Robert P. Giugliano et al. New England Journal of Medicine
  4. A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia (2014)
    Dirk Blom, Tomas Hala et al. New England Journal of Medicine
  5. Safety and Efficacy of a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease, SAR236553/REGN727, in Patients With Primary Hypercholesterolemia Receiving Ongoing Stable Atorvastatin Therapy (2012)
    James M. McKenney, Michael J. Koren et al. Journal of the American College of Cardiology
  6. Anti-PCSK9 Monotherapy for Hypercholesterolemia (2014)
    Michael J. Koren, Michael A. Bolognese et al. Journal of the American College of Cardiology
  7. Reduction in Lipoprotein(a) With PCSK9 Monoclonal Antibody Evolocumab (AMG 145) (2014)
    Frederick J. Raal, Robert P. Giugliano et al. Journal of the American College of Cardiology
  8. Single Ascending Dose Study of a Short Interfering RNA Targeting Lipoprotein(a) Production in Individuals With Elevated Plasma Lipoprotein(a) Levels (2022)
    Steven E. Nissen, Kathy Wolski et al. JAMA
  9. Preclinical development and phase 1 trial of a novel siRNA targeting lipoprotein(a) (2022)
    Michael J. Koren, Patrick M. Moriarty et al. Nature Medicine
  10. Single Ascending and Multiple-Dose Trial of Zerlasiran, a Short Interfering RNA Targeting Lipoprotein(a) (2024)
    Steven E. Nissen, Kathy Wolski et al. JAMA

Immediate Impact

1 by Nobel laureates 1 from Science/Nature 105 standout
Sub-graph 1 of 11

Citing Papers

Lepodisiran — A Long-Duration Small Interfering RNA Targeting Lipoprotein(a)
2025 Standout
Lipoprotein(a) and cardiovascular disease
2024 Standout
36 intermediate papers

Works of Michael J. Koren being referenced

Single Ascending Dose Study of a Short Interfering RNA Targeting Lipoprotein(a) Production in Individuals With Elevated Plasma Lipoprotein(a) Levels
2022 Standout
Preclinical development and phase 1 trial of a novel siRNA targeting lipoprotein(a)
2022 Standout
and 14 more

Author Peers

Author Last Decade Papers Cites
Michael J. Koren 6258 2421 3757 99 10.0k
A R Lorimer 5843 1612 2714 111 9.3k
Michael Clearfield 5774 1612 2132 64 8.4k
Thomas Cole 6222 1673 2625 63 9.5k
T. A. Miettinen 5815 1617 2311 50 8.9k
John C. LaRosa 6632 1969 3348 119 11.0k
Gregory G. Schwartz 6233 1285 3596 196 9.9k
Christopher J. Packard 7493 1778 2640 92 11.2k
David Kallend 5136 1103 1737 98 7.4k
Scott M. Wasserman 10609 3994 2617 126 13.9k
Chuan‐Chuan Wun 4928 1522 2816 33 7.6k

All Works

Loading papers...

Rankless by CCL
2026